Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy

키워드

참고문헌 (37)

1. Centorrino F, "Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits", Am J Psychiatry, 161, pp.700~706 (2004)
2. Stahl SM, "High-cost use of second-generation antipsychotics under California's Medicaid program", Psychiatr Serv, 57, pp.127~129 (2006)
3. Correll CU, "Does antipsychotic polypharmacy increase the risk for metabolic syndrome?", Schizophr Res, 89, pp.91~100 (2007)
4. Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, pp.1~11 (2012)
5. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
6. Lehman AF, "American Psychiatric Association;Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2Suppl), pp.1~56 (2004)
7. 안용민, "한국형 정신분열병 약물치료 알고리듬의 임상 적용 가능성(II): 적용상의 문제점 및 향후 개정 방향", 대한정신약물학회지, 17(1), pp.35~49 (2006), 대한정신약물학회
8. Paton C, "Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients", J Psychopharmacol, 17, pp.223~229 (2003)
9. Procyshyn RM, "Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients", J Clin Psychiatry, 71, pp.566~573 (2010)
10. Santone G, "Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy", Pharmacoepidemiol Drug Saf, 20, pp.441~449 (2011)
11. Sim K, "Antipsychotic polypharmacy in patients with schizophrenia:a multicentre comparative study in East Asia", Br J Clin Pharmacol, 58, pp.178~183 (2004)
12. Suokas JT, "Description of long-term polypharmacy among schizophrenia outpatients", Soc Psychiatry Psychiatr Epidemiol, 48, pp.631~638 (2013)
13. Stahl SM, "A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation", Curr Med Chem, 11, pp.313~327 (2004)
14. Gilmer TP, "Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004", Psychiatr Serv, 58, pp.1007~1010 (2007)
15. Gallego JA, "Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)
16. Chong MY, "Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change", Psychiatry Clin Neurosci, 58, pp.61~67 (2004)
17. 심인희, "정신건강의학과 입원 환자의 항정신병약물 사용 변화: 일 대학병원에서 1997년, 2003~2004년과 2009~2010년의 비교", 대한정신약물학회지, 23(2), pp.57~64 (2012), 대한정신약물학회[DOI]
18. Vares M, "Concomitant medication of psychoses in a lifetime perspective", Hum Psychopharmacol, 26, pp.322~331 (2011)
19. Hye Jin Choi, "Antipsychotics Prescribing Patterns of Patients with Schizophrenia Admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008", Clinical Psychopharmacology and Neuroscience, 9(1), pp.17~22 (2011), 대한정신약물학회
20. American Psychiatric Association, "Practice guideline for the treatment of patients with schizophrenia", Am J Psychiatry, 154, pp.1~63 (1997)
21. Woods SW., "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
22. Haro JM, "SOHO Study Group. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia", Acta Psychiatr Scand Suppl, (416), pp.16~23 (2003)
23. Patrick DL, "Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia", Curr Med Res Opin, 25, pp.325~338 (2009)
24. Nasrallah H, Morosini P, "Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia", Psychiatry Res, 161, pp.213~224 (2008)
25. Xiang YT, "Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009)", Pharmacopsychiatry, 45, pp.7~12 (2012)
26. 김태석, "일산화탄소 중독과 관련된 정신병적 증상 및 파킨슨 증상이 동반된 환자에서의 Aripiprazole 치료 1예", 대한정신약물학회지, 16(2), pp.163~168 (2005), 대한정신약물학회
27. 배승오, "한국형 정신분열병 약물치료 알고리듬의 임상 적용 가능성 (I): 치료효과 측면에서의 분석", 대한정신약물학회지, 17(1), pp.24~34 (2006), 대한정신약물학회
28. Voruganti L, "Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life", Schizophr Res, 43, pp.135~145 (2000)
29. Leucht S, "Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo", A meta-analysis of randomized controlled trials. Schizophr Res, 35, pp.51~68 (1999)
30. 우영섭, "정신분열병 환자에서 비정형 항정신병약물과 항콜린성 약물의 병합 사용：예비 연구", 대한정신약물학회지, 17(2), pp.174~180 (2006), 대한정신약물학회
31. Wang PS, "Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders", Schizophr Bull, 26, pp.451~457 (2000)
32. Correll CU, "Antipsychotic combinations vs monotherapy in schizophrenia:a meta-analysis of randomized controlled trials", Schizophr Bull, 35, pp.443~457 (2009)
33. Ganguly R, "Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000", J Clin Psychiatry, 65, pp.1377~1388 (2004)
34. Shinfuku N, "Pharmacotherapy for schizophrenic inpatients in East Asia-changes and challenges", Int Rev Psychiatry, 20, pp.460~468 (2008)
35. Tiihonen J, "Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia", Arch Gen Psychiatry, 69, pp.476~483 (2012)
36. Volavka J, "Heterogeneity of violence in schizophrenia and implications for long-term treatment", Int J Clin Pract, 62, pp.1237~1245 (2008)
37. Cascade EF, "Current management of schizophrenia: antipsychotic monotherapy versus combination therapy", Psychiatry (Edgmont), 5, pp.28~30 (2008)

관련 논문AI추천